If you’ve searched for weight loss medications recently, you’ve probably noticed that Zepbound and Wegovy and Ozempic all seem to get mentioned in the same breath.
They’re covered by the same news outlets, prescribed for the same conditions, and discussed in the same online communities. It’s completely understandable to assume they’re versions of the same drug, or that Zepbound is just a brand name for semaglutide.
It isn’t. Zepbound contains tirzepatide, which is a different molecule from semaglutide in meaningful ways. Both are effective treatments for obesity. Both work through related but distinct mechanisms.
And the choice between them isn’t as simple as picking one brand over another; it’s a pharmacological question that’s worth understanding before you have that conversation with a provider.
Drug selection should be based on your provider’s assessment of your individual health needs.
Zepbound Does Not Contain Semaglutide
This is the short answer to the question in the title: no, Zepbound is not a semaglutide product.
Zepbound is the brand name for tirzepatide, approved by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Tirzepatide is also sold under the brand name Mounjaro, which carries the same approval for type 2 diabetes.
Semaglutide is a completely separate molecule, sold under the brand names Wegovy (for weight management) and Ozempic (for type 2 diabetes). The two drugs are not interchangeable, do not contain the same active ingredient, and are not manufactured by the same company. Tirzepatide comes from Eli Lilly. Semaglutide comes from Novo Nordisk.
The confusion is understandable partly because both medications belong to a broader drug category that includes GLP-1 receptor agonists. But belonging to the same category doesn’t mean they’re the same drug, any more than two different antibiotics being “antibiotics” means they work identically.
What Semaglutide Is
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking GLP-1, a hormone your gut releases after eating, which signals the brain to reduce hunger, slows the rate at which the stomach empties, and improves insulin secretion in response to blood sugar.
The result is that people eat less, feel fuller sooner, and often experience significant weight loss over months of treatment. In the STEP-1 trial, once-weekly semaglutide at 2.4mg produced a mean body weight reduction of about 15% at 68 weeks.
Semaglutide is delivered as a once-weekly subcutaneous injection and has been available in its approved obesity dose since 2021. Compounded versions have been widely used during periods of branded shortage.
You can read more about how compounded semaglutide works within a medically supervised program at Precision Telemed.
What Tirzepatide Is
Tirzepatide is a dual agonist, meaning it activates two different receptors rather than one. It targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously.
GIP is a gut hormone that works alongside GLP-1 in regulating insulin secretion, energy metabolism, and fat storage. GIP receptors are found not just in the gut and pancreas but in adipose tissue and the brain, which is why activating both pathways together produces metabolic effects that go beyond what GLP-1 agonism alone achieves.
This dual mechanism is what makes tirzepatide pharmacologically distinct from semaglutide. It’s not simply a stronger version of the same approach; it’s a different approach that happens to overlap with semaglutide on the GLP-1 side. Our post on compounded tirzepatide as a dual-action peptide goes into more depth on the mechanistic differences.
How Their Mechanisms Translate in Practice
The practical difference between GLP-1 only (semaglutide) and dual GLP-1/GIP (tirzepatide) shows up in the clinical data.
The SURMOUNT-5 trial, published in the New England Journal of Medicine in May 2025, was the first head-to-head comparison between tirzepatide and semaglutide for weight loss in adults with obesity without diabetes. In 751 participants randomized to receive the maximum tolerated dose of either medication over 72 weeks, tirzepatide produced a mean body weight reduction of 20.2%, compared to 13.7% for semaglutide. Tirzepatide also produced greater improvements in waist circumference and several cardiometabolic markers.
Gastrointestinal side effects leading to treatment discontinuation were reported more frequently with semaglutide (5.6%) than with tirzepatide (2.7%), which researchers partly attributed to GIP’s counterregulatory effects on GLP-1-driven nausea pathways.
These are meaningful clinical differences. They’re also not the only factors that determine which medication is right for an individual patient.
Why Neither Drug Is Automatically Better for Everyone
Head-to-head data showing one drug outperformed another at the group level doesn’t mean every person responds the same way. Individual response to these medications varies considerably, for reasons that aren’t fully predictable before treatment starts.
Some people achieve excellent results on semaglutide and tolerate it well. Others respond more strongly to tirzepatide’s dual mechanism, or find that the tolerability profile suits them better. Access, cost, insurance coverage, and individual health factors all play into which treatment makes the most sense in a given situation.
There are also clinical contexts where one medication may be preferred over the other. A patient’s metabolic profile, history of GI issues, blood sugar patterns, existing medications, and specific health goals all factor into a well-reasoned prescribing decision. Someone with a history of significant nausea on GLP-1 medications, for instance, might benefit from the evidence suggesting tirzepatide’s GIP component moderates some of those GI effects. Someone already doing well on semaglutide has little reason to switch. These are nuanced, individualized calls. That conversation belongs in a clinical visit, not a product comparison page.
The compounded versions of both drugs, available through programs like the one at Precision Telemed, offer an accessible path to treatment for many patients who face cost or availability barriers with branded versions.
Clearing Up the Brand Confusion
Brand names in this drug category can be genuinely confusing. Multiple products, two different active ingredients, two different companies, and overlapping use cases across diabetes and obesity make it easy for even attentive patients to mix things up. Here’s a plain-language overview of which drug is which.
Semaglutide products:
- Wegovy (semaglutide 2.4mg, FDA-approved for weight management)
- Ozempic (semaglutide 0.5mg to 2mg, FDA-approved for type 2 diabetes)
- Rybelsus (oral semaglutide, FDA-approved for type 2 diabetes)
Tirzepatide products:
- Zepbound (tirzepatide, FDA-approved for weight management)
- Mounjaro (tirzepatide, FDA-approved for type 2 diabetes)
The on-label weight management approvals for both drug classes are for the higher-dose versions: Wegovy for semaglutide and Zepbound for tirzepatide. Both Ozempic and Mounjaro are formally diabetes treatments, though both are commonly discussed in the context of weight loss.
Understanding which active molecule is in which product is the first step toward having a more informed conversation with your prescribing provider about what might be the right fit for you.
If you’re trying to sort out which of these two drug classes makes more sense for your situation, a Precision Telemed provider can walk through your health history, metabolic markers, and goals with you and help you make a well-informed decision. Get started with a consultation!
Drug selection should be based on your provider’s assessment of your individual health needs. This content is for informational purposes only and does not constitute medical advice.